Stocklytics Platform
Asset logo for symbol RVNC
Revance Therapeutics
Penny Stock
Asset logo for symbol RVNC


Key Stats
Prev. Close$3.27
Next Earnings Date-
Dividend Yield %-
Market Cap$341.54M
PE Ratio-
Day Range3.33
52 Week Range2.30
P/B Ratio12.30
Operating M. %-90.16%
Earnings Growth %9.10%
EBITDA Margin %-90.49%
ROE %-2,096.78%
Gross Profit$145.98M
Total Debt$475.77M
P/S Ratio1.8x
Enterprise to EBITDA-2.26
Profit Margin-132.12%
Debt/Equity Ratio-
Payout Ratio-
Industry average yield2.95%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_up0.81%
US Marketarrow_drop_up1.43%
RVNC / Market
RVNC exceeded the US Market which returned 1.43% over the last twenty four hours.
RVNC / Healthcare Sector
RVNC exceeded the US Healthcare sector which returned 0.81% over the last twenty four hours.

Revance Therapeutics (RVNC) Statistics

Revance Therapeutics Inc (RVNC) is a biotechnology company focused on developing and commercializing innovative therapies for aesthetic and therapeutic indications. The company's primary product candidate is DaxibotulinumtoxinA, a neuromodulator that has the potential to be used in a variety of therapeutic and aesthetic indications. Revance's stock statistics show that it has a market capitalization of $2.5 billion, with a current share price of $32.50. The company's valuation metrics indicate a price to sales ratio of 15.8 and a price to book ratio of 4.2. These metrics suggest that the stock may be relatively undervalued compared to its peers in the biotechnology sector.

In terms of fundamentals, Revance Therapeutics Inc has demonstrated strong revenue growth over the past few years. The company's revenue per share has increased from $0.23 in 2016 to $1.47 in 2020, representing a compound annual growth rate of 43%. This impressive growth is driven by the company's focus on developing a robust pipeline of innovative products. Revance's enterprise to EBITDA ratio stands at 96.2, indicating that the company may have a relatively high level of debt. However, its profit margin is 78.5%, demonstrating its ability to generate significant profits from its operations. In addition, Revance Therapeutics Inc has a total debt of $239.2 million, which represents a relatively low debt burden compared to its market capitalization.

add Revance Therapeutics  to watchlist

Keep an eye on Revance Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has Revance Therapeutics (RVNC) stock's performance compared to its sector and the market over the past year?

Over the past year, Revance Therapeutics (RVNC) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 24.24%, Revance Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 55.20%, it has fallen short of the market average. This comparison highlights Revance Therapeutics 's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of Revance Therapeutics (RVNC) stock?

The PE ratio for Revance Therapeutics (RVNC) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

What is the EPS of Revance Therapeutics (RVNC) stock?

The Earnings Per Share (EPS) for Revance Therapeutics (RVNC), calculated on a diluted basis, is -$4.12. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of Revance Therapeutics (RVNC) stock?

The operating margin for Revance Therapeutics (RVNC) is -90.16%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of Revance Therapeutics (RVNC) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Revance Therapeutics (RVNC) is -$211.79M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does Revance Therapeutics (RVNC) have?

Revance Therapeutics (RVNC) has a total debt of $475.78M. The net debt, which accounts for cash and cash equivalents against the total debt, is $342.62M.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level